Sanofi’s LEAP2MONO phase 3 study of venglustat to treat type 3 Gaucher disease meets all primary endpoints: Paris Tuesday, February 3, 2026, 13:00 Hrs [IST] Positive results fro ...
On February 2, 2026, Sanofi entered a mandate with an investment service provider for this program. Under the terms of the mandate, Sanofi will repurchase its own shares for a total consideration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results